Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Withdrawn 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 2Colorectal Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1

Interventions

pembrolizumab 75Carboplatin 46Paclitaxel 44130-nm albumin-bound paclitaxel 35Gemcitabine 34Cyclophosphamide 23Capecitabine 22Nivolumab 21Albumin-Bound Paclitaxel 21atezolizumab 20sacituzumab govitecan 14spartalizumab 13Doxorubicin 11olaparib 9Cisplatin 9Bevacizumab 9eribulin 8fludarabine 7durvalumab 7avelumab 7Injections 7Fulvestrant 7Fluorouracil 7Vinorelbine 6Leucovorin 6Docetaxel 6iniparib 5budigalimab 5Ipilimumab 5Epirubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Triple Negative Breast Neoplasms × yeast-CEA vaccine × Clear all
NCT03175666 2025-02-21

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Breast

Triple Negative Breast Neoplasms

NCT03554109 2025-02-21

TNBC

ImmunityBio, Inc.

Phase 2 Withdrawn
Breast

Triple Negative Breast Neoplasms

NCT03387085 2024-08-09

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

ImmunityBio, Inc.

Phase 1/2 Terminated
9 enrolled 18 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡